Silver Book Fact

A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate
cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in median survival.

Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM. 2010; 363: 411-22. http://www.nejm.org/doi/full/10.1056/NEJMoa1001294

Reference

Title
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Publication
NEJM
Publication Date
2010
Authors
Kantoff, P, C Higano, N Shore, E Berger, E Small, D Penson, et al.
Pages
411-22
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • New Drug Increases Brain Cancer Survival Rate: Temozolomide is the first new drug in over 30 years to treat glioblastoma, a severe form of brain cancer  
  • Without screening and adjuvant therapy, the death rate for breast cancer would have increased by about 30 percent between 1975 and 2000.  
  • Breast cancer incidence rates in women decreased 3.5% per year from 2001-2004, the first decrease observed in 20 years.  
  • Mortality rates for colorectal cancer have declined over the past 2 decades and have had a steeper decline in the most recent time period (1.8% per year from 1985-2002 compared…  
  • Percentage of women age 50 and over who had a mammogram in the past 2 years, by age group, selected years 1987-2005